Advances and challenges in storage, transplantation, expansion and homing of Umbilical Cord Blood Hematopoietic Stem Cells (UCB-HSCs)

Authors

Abstract:

Abstract Background and Objectives Umbilical cord blood hematopoietic stem cells (UCB-HSCs) have high potential capabilities in the treatment of hematological and non-hematological disorders. Awareness of biology, self-renewal, homing, expansion, storage, and transplantation can lead to optimal use of these cells.   Materials and Methods In this Review article in order to investigate the advances and challenges in cord blood banks, the expansion, storage, homing and transplantation of umbilical cord blood stem cells, we used key words like umbilical cord blood, hematopoietic stem cells and stem cell banks for searching published articles in the PubMed database during 2000 to 2020.   Results Over time, many advances in biology, expansion, storage, and transplantation of cord blood cells have been made by researchers around the world with a growth in the number of private and public cord blood banks in parallel. Despite these advances, there are still challenges to the optimal use of these cells.   Conclusions  Increasing our awareness about the achievements and shortcomings in the area of UCB-HSCs, can lead to the formation of new strategies and further studies for the optimal use of these cells.  

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Nanofiber Expansion of Umbilical Cord Blood Hematopoietic Stem Cells

Background The aim of this study was the ex vivo expansion of Umbilical Cord Blood hematopoietic stem cells on biocompatible nanofiber scaffolds. Materials and Methods CD133+ hematopoietic stem cells were separated from umbilical cord blood using MidiMacs (positive selection) system by means of monocolonal antibody CD133 (microbeads) subsequently, flowcytometry method was done to asses...

full text

nanofiber expansion of umbilical cord blood hematopoietic stem cells

background the aim of this study was the ex vivo expansion of umbilical cord blood hematopoietic stem cells on biocompatible nanofiber scaffolds. materials and methods cd133+ hematopoietic stem cells were separated from umbilical cord blood using midimacs (positive selection) system by means of monocolonal antibody cd133 (microbeads) subsequently, flowcytometry method was done to assess the pur...

full text

Nanofiber Expansion of Umbilical Cord Blood Hematopoietic Stem Cells.

BACKGROUND The aim of this study was the ex vivo expansion of Umbilical Cord Blood hematopoietic stem cells on biocompatible nanofiber scaffolds. MATERIALS AND METHODS CD133+ hematopoietic stem cells were separated from umbilical cord blood using MidiMacs (positive selection) system by means of monocolonal antibody CD133 (microbeads); subsequently, flowcytometry method was done to assess the ...

full text

Advances in Hematopoietic Stem Cell Mobilization and Peripheral Blood Stem Cell Transplantation

Hematopoietic stem/progenitor cells (HSPCs) which give rise to different blood cell types are present within the bone marrow microenvironment, especially in flat bones such as skull, vertebrae, pelvis and chest. Interacting factors such as stromal derived factor-1/CXCR4, very late antigen-4/vascular cell adhesion molecule-1, Lymphocyte function-associated antigen-1/ intercellular adhesion molec...

full text

CD26+ Cord Blood Mononuclear Cells Significantly Produce B, T, and NK Cells

Background: Umbilical cord blood (UCB) is an alternative source of hematopoietic stem cell transplantation (HSCT), used in Leukemia treatment. CD26+ cells, a fraction of CD34 positive cells, are a major population of UCB cells which negatively regulate the in vivo homing and engraftment of HSCs. CD26 is highly expressed in various cells such as HSCs, immune cells, fibroblasts, and epithelial ce...

full text

Hematopoietic stem-cell transplantation using umbilical-cord blood cells.

In the recent years, umbilical cord blood (UCB) has emerged as an alternative source of hematopoietic progenitors (CD34+) for allogeneic stem cell transplantation, mainly in patients lacking an HLA-matched marrow donor. Since 1998, about 2500 patients have received UCB transplants for a variety of malignant and non-malignant diseases. The vast majority of recipients were children with an averag...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 17  issue 3

pages  226- 241

publication date 2020-10

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

No Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023